Effect of scheduled monitoring of liver function during anti-Tuberculosis treatment in a retrospective cohort in China
详细信息 查看全文
- 作者：Shanshan Wu (1)
Yinyin Xia (2)
Xiaozhen Lv (1)
Yuan Zhang (1)
Shaowen Tang (1)
Zhirong Yang (1)
Dehua Tu (3)
Peiyuan Deng (4)
Shiming Cheng (2)
Xiaomeng Wang (5)
Yanli Yuan (6)
Feiying Liu (7)
Daiyu Hu (8)
Siyan Zhan (1) - 关键词：Tuberculosis ; Hepatotoxicity ; Monitoring
- 刊名：BMC Public Health
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：183KB
- 参考文献：1. WHO: / Global tuberculosis control: WHO Report 2011. WHO document WHO/CDS/TB; 2011.
2. WHO: / An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. WHO document WHO/CDS/TB; 2002:1-0.
3. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D: Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. / Am J Respir Crit Care Med 2003, 167:1472-477. CrossRef
4. Kaona FA, Tuba M, Siziya S, Sikaona L: An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. / BMC Public Health 2004, 4:68. CrossRef
5. Wares DF, Singh S, Acharya AK, Dangi R: Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. / Int J Tuberc Lung Dis 2003, 7:327-35.
6. WHO: / Anti-tuberculosis drug resistance in the world report no. 4. WHO/HTM/TB/2008.394; 2008.
7. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C: Tuberculosis. / Lancet 2003, 362:887-99. CrossRef
8. WHO: / Treatment of tuberculosis: guidelines for national programs. WHO/TB/97220; 1997.
9. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloguin CA, Gordin FM, Nunes D, Strader DB, Bernardo J, Venkataramanan R, Sterling TR: ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee: An official ATS statement: hepatotoxicity of antituberculosis therapy. / Am J Respir Crit Care Med 2006, 174:935-52. CrossRef
10. Joint Tuberculosis Committee of the British Thoracic Society: Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. / Thorax 1998, 53:536-48. CrossRef
11. Migliori GB, Raviglione MC, Schaberg T, Davies PDO, Zellweger JP, Grzemska M, Mihaescu T, Clancy L, Casali L: Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organization (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. / Eur Respir J 1999, 14:978-92. CrossRef
12. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. / J Gastroenterol Hepatol 2008, 23:192-02. CrossRef
13. Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, Tu DH, Chen YX, Zhou L, Zhu LZ, Gao WW, Wang HY, Chen DF, Yang L, He PP, Li XT, He YJ, Sun F, Zhan SY: Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). / BMC Public Health 2010, 10:267. CrossRef
14. Shang P, Xia Y, Liu F, Wang X, Yuan Y, Hu D, Tu D, Chen Y, Deng P, Cheng S, Zhou L, Ma Y, Zhu L, Gao W, Wang H, Chen D, Yang L, He P, Wu S, Tang S, Lv X, Shu Z, Zhang Y, Yang Z, Chen Y, Li N, Sun F, Li X, He Y, Garner P, / et al.: Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. / PLoS One 2011, 6:e21836. CrossRef
15. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T: Variable selection for propensity score models. / Am J Epidemiol 2006, 163:1149-156. CrossRef
16. Senousy BE, Belal SI, Draganov PV: Hepatotoxic effects of therapies for tuberculosis. / Nat Rev Gastroenterol Hepatol 2010, 7:543-56. CrossRef
17. World Health Organization Division of Traditional Medicine: / General Guidelines for Methodologies on Research and Evaluation of Traditional Medicines. WHO, Geneva; 2000.
18. Liu Q, Garner P, Wang Y, Huang B, Smith H: Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. / BMC Public Health 2008, 8:365. CrossRef
19. Austin PC: An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. / Multivariate Behav Res 2011, 46:399-24. CrossRef
20. Baser O: Too much ado about propensity score models? Comparing methods of propensity score matching. / Value Health 2006, 9:377-85. CrossRef
21. D-Agostino RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. / Stat Med 1998, 17:2265-281. CrossRef
22. Lunceford JK, Davidian M: Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. / Stat Med 2004, 23:2937-960. CrossRef
23. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM: Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. / Am J Epidemiol 2006, 163:262-70. CrossRef
24. Stürmer T, Rothman KJ, Glynn RJ: Insights into different results from different causal contrasts in the presence of effect-measure modification. / Pharmacoepidemiol Drug Saf 2006, 15:698-09. CrossRef
25. Agal S, Baijal R, Pramanik S, Patel N, Gupte P, Kamani P, Amarapurkar D: Monitoring and management of antituberculosis drug induced hepatotoxicity. / Gastroenterol Hepatol 2005, 20:1745-752. CrossRef
26. McNeill L, Allen M, Estrada C, Cook P: Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. / Chest 2003, 123:102-06. CrossRef
27. Byrd RB, Horn BR, Solomon DA, Griggs GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1000 patients. / JAMA 1979, 241:1239-241. CrossRef
28. Shah BR, Laupacis A, Hux JE, Austin PC: Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. / J Clin Epidemiol 2005, 58:550-59. CrossRef
29. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/12/454/prepub - 作者单位：Shanshan Wu (1)
Yinyin Xia (2)
Xiaozhen Lv (1)
Yuan Zhang (1)
Shaowen Tang (1)
Zhirong Yang (1)
Dehua Tu (3)
Peiyuan Deng (4)
Shiming Cheng (2)
Xiaomeng Wang (5)
Yanli Yuan (6)
Feiying Liu (7)
Daiyu Hu (8)
Siyan Zhan (1)
1. Department of Epidemiology and Bio-statistics, School of Public Health, Peking University Health Science Centre, 38 Xueyuan Road, Haidian District, Beijing, 100191, China
2. Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
3. Beijing Institute for Tuberculosis Control, Beijing, China
4. Center for Drug Reassessment, State Food and Drug Administration, Beijing, China
5. Center for Disease Control and Prevention in Zhejiang Province, Hangzhou, China
6. Center for Disease Control and Prevention in Jilin Province, Changchun, China
7. Center for Disease Control and Prevention in Guangxi Zhuang Autonomous Region, Nanning, China
8. Center for Disease Control and Prevention in Chongqing Municipality, Chongqing, China - ISSN：1471-2458
文摘
Background Data on effect of regular liver function monitoring during anti-TB treatment is limited in China. This study aimed to evaluate the effects of scheduled liver function monitoring on identification of asymptomatic liver damage and anti-TB treatment outcomes during anti-TB treatment. Methods A retrospective analysis was performed based on a national-level cohort study. A total of 273 patients developing liver dysfunction were divided into two groups, 111 patients who were diagnosed through scheduled liver function test within two months after initiation of anti-TB treatment formed scheduled monitoring group, others who were diagnosed due to developing symptoms formed passive detection group (n--62). The two groups were compared through clinical features, prognosis of liver dysfunction and impact on anti-TB treatment using propensity score weighting analysis. Results 33.3% of 273 patients did not have any clinical symptoms, including 8 with severe hepatotoxicity. 1.8% in scheduled monitoring group and 11.1% in passive detection group required hospitalization (P--.004). Regarding the prognosis of liver dysfunction, most patients recovered, no death happened in scheduled monitoring group while 3 died in passive detection group. In terms of impact on anti-TB treatment, 35.1% in scheduled monitoring group and 56.8% in passive detection group changed their anti-TB treatment (P--.001). Conclusions Scheduled monitoring is effective in identifying asymptomatic liver damage, reducing hospitalization rate and improving compliance of anti-TB treatment.